Scheer, S and Ackloo, S and Medina, TS and Schapira, M and Li, F and Ward, JA and Lewis, AM and Northrop, JP and Richardson, PL and Kaniskan, HÜ and Shen, Y and Liu, J and Smil, D and McLeod, D and Zepeda-Velazquez, CA and Luo, M and Jin, J and Barsyte-Lovejoy, D and Huber, KVM and De Carvalho, DD and Vedadi, M and Zaph, C and Brown, PJ and Arrowsmith, CH (2019)A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nature Communications, 10 (1).

Downloaded from: http://e-space.mmu.ac.uk/624968/

Version: Published Version

Publisher: Nature Research

DOI: https://doi.org/10.1038/s41467-018-07905-4

Usage rights: Creative Commons: Attribution 4.0

Please cite the published version
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling

Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative characterization of the probe collection with respect to their potency, selectivity, and mode of inhibition. We demonstrate the utility of this collection in CD4+ T cell differentiation assays revealing the potential of individual probes to alter multiple T cell subpopulations which may have implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and maintaining lineage integrity. This chemical probe collection and associated data form a resource for the study of methylation-mediated signaling in epigenetics, inflammation and beyond.
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes and maintains normal cellular phenotypes, but contributes to disease when dysregulated. The epigenetic state of a cell evolves in an ordered manner during cellular differentiation and epigenetic changes mediate cellular plasticity that enables reprogramming. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the histone proteins that package DNA. The primary heritable modifications of histones include lysine acetylation, lysine mono-, di-, or tri-methylation, and arginine methylation. Collectively these modifications establish chromatin states that determine the degree to which specific genomic loci are transcriptionally active.

Proteins that read, write, and erase histone (and non-histone) covalent modifications have emerged as druggable classes of enzymes and protein–protein interaction domains. Histone deacetylase (HDAC) inhibitors and DNA hypomethylating agents have been approved for clinical use in cancer and more recently clinical trials have been initiated for antagonists of the BET bromodomain proteins (which bind to acetyllysine on histones). The protein methyltransferases EZH2, DOT1L, and PRMT5, and the lysine demethylase LSD1 are transcription factors such as p53, estrogen receptors, and cytosolic signaling factors such as MAP3K2. In addition to histone modification, arginine methylation plays an important role in the function of RNA-binding proteins, ribosome biogenesis and splicing. Thus, this collection of chemical probes constitutes a broad resource to link enzyme activity to a wide range of epigenetic and non-epigenetic methylation-mediated signaling pathways and biology.

PMT chemical probes are potent, selective and cell-penetrant. The development of these chemical probes was guided by principles practiced in the pharmaceutical industry to test the link between a specific protein and a putative biological or phenotypic cellular trait. A useful chemical probe should be reasonably potent in cells, selective for the intended target protein, and free of confounding off-target activities.

The chemical probes described here were each discovered using a biochemical enzymatic assay for the respective recombinant protein, or in some cases the relevant recombinant multiprotein enzyme complex, where the probe has been demonstrated to have an on-target potency with IC₅₀ < 100 nM (Table 1). Each probe was evaluated in a customized cellular assay that tested the ability of the probe to reduce the level of methylation of its substrate in cells. All probes have significant, on-target cellular activity at 1 μM making them useful tools for cellular studies. Importantly, these chemical probes are highly selective for their target protein (Fig. 1c); each has been screened against a collection of up to 34 human SAM-dependent histone, DNA and RNA methyltransferases. The chemical probes within the lysine methyltransferase family are highly selective with measurable cross reactivity only seen between very closely related proteins such as G9a and GLP, or SUV420H1 and SUV420H2. Selectivity within the PRMT family, however, is more difficult to achieve, and a greater degree of cross reactivity is seen in this subfamily. The probes had minimal or no off-target activities when screened against a panel of 119 membrane receptors and ion channels, and kinases (Supplementary Table 1).

Importantly, most chemical probes are accompanied by a structurally similar control compound that has similar physical-chemical properties but is inactive or much less active on its target enzyme (Table 1, Supplementary Tables 1 and 2). These inactive compounds are to be used alongside the active probe to control for unanticipated off-target activity of their common chemical scaffold. In cases where an appropriate control molecule could not be identified, an alternative strategy is to use multiple chemical probes with different chemotypes that inhibit the same target (Table 1 and Supplementary Table 2). Many of the PMTs discussed here have two or more chemical probes with different chemotypes, mechanisms of action, and/
or potency profile. By using multiple diverse chemical probes that inhibit the same target, the user can build confidence in the link between cellular phenotype and inhibition of a specific target.

Multiple mechanisms to inhibit PMTs. The methyl-donating cofactor S-adenosylmethionine (SAM) and methyl-accepting substrate of protein methyltransferases bind at juxtaposed but distinct sites that can each be targeted by small molecule
Fig. 1 Summary of chemical probes. a Phylogenetic trees of human PR and SET domain lysine methyltransferases (upper tree), and the β-barrel fold enzymes (lower tree). Trees are annotated to show chemical probes in this collection that inhibit PKMTs (turquoise circle), a Rossman fold PKMT (dark red square), monomethyl and asymmetric dimethyl PRMTs (blue triangle), symmetric dimethyl PRMTs (orange triangle); and methyltransferase protein complexes (purple star). The number of annotations adjacent to each target is equal to the number of chemical probes for that target. b Detailed coverage of the major histone H3 and H4 methyl marks modulated by this collection of chemical probes. The methylated lysine (K) and arginine (R) residues are annotated in bold font. The PMTs that write the marks are shown with green (PKMTs) or blue (PRMTs) borders, along with the chemical probes that inhibit these PMTs. Also included are non-histone substrates (gray ovals) of PRMT5, SETD7, and SMYD2. c Selectivity of each chemical probe has been assessed against 34 SAM-dependent methyltransferases. SKI-73 and SGC3027 are pro-drugs and selectivity was determined on the respective active components. See also Supplementary Tables 1-3. SAM -adenosylmethionine, SAH -adenosylhomocysteine, me methyl, me2a asymmetric dimethyl, me2s symmetric dimethyl, me2/3 di- and tri-methyl marks are written by the same enzyme.

Table 1 Summary of chemical probes and their chemotype-matched controls for protein methyltransferases. Related to Fig. 1a-c, Supplementary Figs. 1 and 2

| Target          | Probe         | In vitro ICS50 or Kd (nM) | Cell line: assay | ICS50 (nM) | Control     |
|-----------------|---------------|---------------------------|------------------|------------|-------------|
| WDR5⁴           | OICR-9429¹⁴   | 64                        | HEK293: disrupt interaction of WDR5b with MLL1 & RbB55       | 223 & 458  | OICR-0547   |
| EED⁵            | A-395⁶        | 34                        | RD: ↓ H3K27me3                                           | 90         | A-395N      |
| EZH2_H1         | GSK343⁶³      | 4                         | HCC1B86: ↓ H3K27me3                                      | 250        | UNC2400     |
| DOT1L           | SGC0946¹²     | 0.3                       | MCF10A: ↓ H3K27me3                                      | 124        | SGC0649     |
| G9a & GLP       | A-366⁶        | 4 & 38                    | MCF10A, A431: ↓ H3K79me2                                  | 10.3       | Use UNC0642 |
| G9a & GLP       | UNC0642¹⁰     | <3                       | PC3: ↓ H3K9me2                                           | 300        | Use A-366   |
| SUV420H1/2      | A-196⁹       | 21                       | U2OS: ↓ H4K20me2/3                                       | 130        | Use A-197   |
| SMYD2           | BAY-598⁹⁵⁷   | 27                       | HEK293, SMYD2:↓ p53K370me                                 | 58         | BAY-369     |
| SMYD3           | BAY-603⁵⁵⁷   | 88                       | HeLa, SMYD3:↓ MEK2K260me3                                | 10         | BAY-444     |
| SETD7           | (R)-PFI-2²⁷   | 2                        | ↑ nuclear YAP                                           | sub-μM     | (S)-PFI-2   |
| Type 1 PRMTs    | MS0237³⁰     | 30,8 (PRMT1,6)            | MCF7 (PRMT1), HEK293 (PRMT6b): ↓ H4R3me2a, ↓ H3R2me2a   | 9,56 (PRMT1,6) | MS094      |
| PRMT3           | SGC707³⁴     | 31                       | HEK293, PRMT3b: ↓ H4R3me2a, ↓ H3R2me2a                   | 91         | YX1         |
| PRMT4           | TP-064⁶⁴     | <10                      | HEK293: ↓ Med2me2a, ↓ Baf155me2a                          | 43, 340    | TP-064N     |
| PRMT4,6         | SKI-73⁹⁶     | 11                       | MCF-7: ↓ Med2me2a, ↓ HEK293: ↓ Med2me2a                  | 540        | SKI-73N     |
| PRMT5           | MS049⁶⁵      | 44,63                    | Med2me2a (PRMT4), ↓ H3R2me2a (PRMT6b)                    | 1400, 970  | MS049N      |
| PRMT5           | GSK591²⁸     | 11                       | Z138: ↓ SmD3me2s                                         | 56         | SGC2096     |
| PRMT5           | LLY-283³¹     | 22                       | MCF7: ↓ SmB8R1me2s                                       | 30         | LLY-284     |
| PRMT7           | SGC3027²⁸    | <2.5                     | C2C12, PRMT7b: ↓ HSP70R469me                             | 2400       | SGC3027N    |

*Subunits required for activity of their respective enzyme complexes
|Cellular assay utilizes exogenous, transfected target
|https://www.thesgc.org/chemical-probes/BAY-6035
|https://www.thesgc.org/chemical-probes/SKI-73
|https://www.thesgc.org/chemical-probes/SGC0946

↓ decrease; ↑ increase

Inhibitors (Fig. 2). Early efforts to inhibit PMTs focused on targeting the SAM binding site in analogy to targeting the ATP binding site of kinases. However, it has been challenging to identify cell-penetrant compounds that bind to the polar SAM binding pocket and no universal methyltransferase inhibitor scaffold or warhead has yet been identified.

The most frequent mode of inhibition for PMTs is binding of the probe within the substrate pocket, thereby preventing substrate binding (Fig. 2a)¹³,2⁶–²⁹. The high selectivity profile of the SET-domain chemical probes is likely related to the high degree of substrate selectivity of these enzymes. These substrate-competitive probes also take advantage of the structural malleability of the substrate-binding groove to remodel the substrate-binding loops for optimal fit (Fig. 2a, gray contours). Interestingly, binding of many of these substrate competitive probes is also dependent on cofactor SAM, which in some cases directly interacts with the probe molecule, and also is known to help stabilize formation of the substrate-binding pocket of SET domain proteins. These contributions of SAM can be a confounding factor when interpreting enzyme inhibitory kinetic data for these probes. In Fig. 2 we have focused on the mechanism of action of each probe based on the structures of their complexes with their target enzyme. The potent SAM competitive inhibitors, SGC0946¹² (Fig. 2b) and LLY-283¹³, have adenosine-like moieties with hydrophobic substituents replacing the methionine of SAM, while UNC1999¹¹ and GSK343³² have a...
Fig. 2 Structural mechanisms of PMT inhibition by chemical probes. 
a Inhibitors of G9a (PDB: 3HNA (GLP with H3K9 substrate) and 4NVQ (A-366)); SUV420H2 (PDB: 4AU7 (mSUV420H2 with H4 substrate) and SUV420H1 (PDB: 5CPR (A-196)); SETD7 (PDB: 1O9S (H3 substrate) and 4JLG (PFI-2)); PRMT5 (PDB: 4GQB (H4 substrate) and 5C92 (GSK591)); SMYD2 (PDB: 3TG5 (p53 substrate) and 5ARG (BAY-598)); SMYD3 (PDB: 5EX0 (MAP3K2 substrate) and (BAY-6035)) all bind in the substrate (peptide) binding pocket. 
b SGC0946 binds in the SAM-binding pocket of DOT1L thereby preventing cofactor binding (PDB ID: 3QOW (SAM), 4ER6 (SGC0946)). LLY-283 also occupies the SAM-binding pocket of PRMT5-MEP50 complex (PDB ID: 4GQB (SAM analog) and 6CKC (LLY-283)). 
c Three distinct modes of allosteric inhibition of protein methyltransferases. SGC707 binds to PRMT3 in an allosteric site that prevents productive formation of the enzyme’s activation helix (PDB ID: 4RYL). OICR-9429 binds to WDR5 and inhibits MLL1 activity by disrupting WDR5-MLL1-RBBP5 complex (PDB ID: 4QL1). A-395 binds to the EED subunit of the PRC2 complex thereby preventing binding of activating peptides (PDB ID: 5K0M).
peptides, resulting in diminished methyltransferase activity of their target protein. This approach allows for the investigation of the molecular interactions within multi-subunit PMT complexes. The allosteric inhibitor SGC0946 occupies a pocket that is 15 Å away from the site of methyl transfer, but prevents the formation of the catalytically competent conformation of the PRMT3 dimer (Fig. 2c, top panel). OICR-9429 and A-395 are antagonists that make use of the peptide binding pocket in the essential WD40 subunits (WDR5 and EED) of the multiprotein MLL1 and PRC2 complexes, respectively (Fig. 2c, middle and bottom panels). OICR-9429 binds in the central pocket of WDR5 preventing the latter’s interactions with MLL and histone peptides, resulting in diminished methyltransferase activity of the complex. A-395 binds in the analogous pocket of EED, thereby preventing its interaction with trimethylated peptides that activate the PRC2 holoenzyme. Both chemical probes burrow into the central cavity of their respective WD40 protein targets occupying a remodeled binding pocket that is significantly larger than that of the peptides which they replace. Thus, a common feature revealed by the co-crystal structures of these probes with their target protein is the significant remodeling of the substrate or allosteric binding sites to selectively accommodate each probe molecule.

A caveat of targeting scaffolding subunits of chromatin complexes is that such proteins are often components of multiple complexes, with diverse functions in cells. For instance, WDR5 interacts with at least 64 different proteins, including the oncprotein c-MYC, and disrupting the WDR5 protein interaction network has diverse functional consequences beyond the MLL complex. In this regard, chemical probes are ideal tools to investigate the biochemical and cellular outcome of targeting a specific protein interaction interface. Taken together, this collection of chemical probes reveals the wide array of mechanisms by which PMTs may be inhibited.

Reagents for specificity and protein interaction studies. Chemical proteomics using affinity reagents derived from chemical probes represents a powerful approach to investigate the molecular target profile of chemical probes and to elucidate protein interaction networks in multiple cell types. In order to facilitate such studies ten affinity reagents were synthesized for seven targets. Of these reagents, three have been previously used to verify the selectivity of their respective chemical probe for the intended target protein, and for an additional five probes (for four targets) we indicate here the recommended site of derivatization (Supplementary Table 2). These suggestions are based on empirical data obtained during each probe discovery program, including target/probe co-crystal structures and chemical structure-activity-relationships (SAR). A further three affinity reagents were used to generate cellular selectivity data for the DOT1L inhibitor SGC0946, the EED antagonist A-395, and the Type I PRMT inhibitor MS023 (Fig. 3). The EED and Type I PRMT affinity reagents specifically enriched their cognate targets from cell lysates as demonstrated by immunoblotting (Supplementary Fig. 1). This enrichment could be competed with the respective underivitized free chemical probe suggesting a specific interaction not affected by immobilization. Profiling of the pan Type I PRMT inhibitor MS023 in HEK293 cell lysates using label-free quantification (LFQ) protein mass spectrometry showed engagement of several PMTs including PRMT1, 3, 4, and 6 and their respective binding partners (Fig. 3a, d, and Supplementary Data 1). PRMT8, which MS023 is known to inhibit, was not detected, consistent with lack of expression in HEK293 cells. The negative control compound MS094 had no effect on PRMT target engagement or interactome. Investigation of the EED antagonist A-395 in G401 cell lysates revealed several well-known PRC2 complex members which were co-purified with the cognate target EED (Fig. 3b, e, and Supplementary Data 2) similar to results obtained with a structurally distinct EED antagonist. As expected, pre-treatment with the negative control A-395N even at high concentration did not affect binding of EED and the other PRC2 complex members to the A-395 affinity matrix, confirming its applicability as an additional tool for EED and PRC2. Che-moproteomic analysis of the DOT1L inhibitor SGC0946 in Jurkat cell lysates indicated that the probe is highly specific for DOT1L, confirming earlier results obtained with HL-60 cells (Fig. 3c and Supplementary Data 3).

Approaches to use the collection. Each chemical probe can be used to investigate the effects of inhibiting the respective PMT in a biochemical or cellular assay. Thus, each probe and its control will be valuable tools in hypothesis-driven research projects. We envision, however, that these tools will be equally valuable in prospective, hypothesis-generating discovery screens to identify specific PMTs whose inhibition is linked with a certain phenotype. To date, much of the research using epigenetic inhibitors has focused on cancer research, with inhibitors of several PMT targets progressing into clinical trials. While these oncology studies are of great interest and medical importance, we sought to systematically investigate the landscape of PMT inhibition in a non-cancer setting, namely CD4+ T helper (Th) cell differentiation.

Regulation of Th cell differentiation by PMTs. Cellular differentiation is guided by chromatin-mediated changes in gene expression in response to extracellular cues. In the immune system, naïve Th cells can adopt a wide range of cellular fates depending upon the external signals received during activation by antigen-presenting cells. For example, interleukin (IL)-12 promotes the development of Th1 cells that express the transcription factor T-bet (Tbx21) and produce interferon (IFN)-γ, while activation in the presence of IL-4 leads to Th2 cells that express GATA-3 and secrete IL-4, IL-5 and IL-13. In addition, Th17 (RORyt-expressing and IL-17A-producing) and induced regulatory T (Treg) cells (FOXP3-expressing) develop from naïve Th cells in the presence of TGFB and IL-6 or TGFB alone, respectively. The magnitude of the immune response to a given stimulus is dependent on the abundance and relative proportions of Th subtypes, and dysregulation of the balance among Th subtypes contributes to diseases such as autoimmunity and cancer.

Previous studies using gene-deficient mice have identified central roles for PMTs including MLL1, G9a, and EZH2 in Th cell differentiation and stability. We tested the effect of inhibiting each methyltransferase on Th cell differentiation, focusing first on IFN-γ-producing Th1 cells (Fig. 4a, b, and Supplementary Figs. 2 and 3). Isolated naïve CD4+ Th cells from the spleen and peripheral lymph nodes of mice with a fluororescent reporter of IFN-γ expression (IFN-γ-YFP mice) were activated for 4 days under Th1 polarizing conditions in the presence of each probe and its respective control compound (when available). Treatment with UNC1999 or GSK343 which target the catalytic subunits of PRC2 (EZH1/2), (but not the control compound UNC2400) significantly increased the expression and production of the signature cytokine IFN-γ under Th1 polarizing conditions. These results are consistent with previous studies showing that T cell-specific deletion of EZH2 resulted in enhanced Th1 cell differentiation in mice. We also observed a significant increase of IFN-γ producing CD4+...
Fig. 3 Affinity Reagents for Chemoproteomics. a Volcano plot of MTM7172-enriched proteome (labeled blue) from HEK293 cell lysate, with targets significantly (FDR = 0.05, SO = 0.2) competed by 20 μM MS023 with respect to 20 μM MS094 negative control. Proteins marked in purple indicate known interactors of the identified direct targets of MS023 close to the significance threshold. b Volcano plot of (A-395)-NH2-enriched proteome (labeled blue) from G401 cell lysate, with targets significantly (FDR = 0.05, SO = 0.2) competed by 20 μM A-395 with respect to 20 μM A-395N negative control. c Volcano plot of SGC2077-enriched proteome (labeled blue) from Jurkat cell lysate, with targets significantly (FDR = 0.05, SO = 0.2) competed by 20 μM SGC0946, with respect to DMSO control. d STRING network evaluation of targets significantly competed by MS023. Lines in the STRING evaluation represent evidenced interactions, with line thickness indicating confidence (high to low). e STRING network evaluation of targets significantly competed by A-395. The chemical structures of the chemical biology reagents, MTM7172, (A-395)-NH2, and SGC2077, are shown in Supplementary Table 2. See also Supplementary Fig. 1.
T cells using A-395 (but not A-395N), an antagonist of the EED subunit of PRC2 which prevents the latter’s enzymatic activity\textsuperscript{35}, demonstrating that the enhanced IFN-γ expression and production was independent of the chemotype of the active probe, further strengthening the link between PRC2 inhibition and Th1 cell differentiation. Our results also identified a role for the H3K79 methyltransferase DOT1L in regulation of Th1 cell differentiation. DOT1L inhibition resulted in an increase in the frequency of viable IFN-γ\textsuperscript{+} CD4\textsuperscript{+} cells and higher production of IFN-γ relative to the control compound and Th1 cells alone (Fig. 4a, b, and Supplementary Figs. 3a and 3b). To further confirm that these observed differentiation phenotypes were related to inhibition of the methyltransferase activity of PRC2 and DOT1L, we performed western blot analyses of the histone methyl marks deposited by each enzyme. Th1 cells treated with UNC1999 or A-395 (but not with the control compounds UNC2400 or A-395N, respectively) showed a significant reduction of H3K27me3 relative to untreated cells.

### Table

| Compound        | Th0 | Th1 | A-395 | A-395N | GSK343 | UNC1999 | UNC2400 | SGC0946 | SGC0649 | A-395N | UNC0642 | A-196 | BAY-598 | BAY-369 | (R)-PFI-2 | MS023 | MS094 | SGC707 | SGC0649 | SGC0946 |
|-----------------|-----|-----|-------|--------|--------|---------|---------|---------|---------|--------|---------|-------|---------|---------|------------|-------|-------|--------|---------|---------|
| WDR5            |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| EED             |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRC2            |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| EZH1/2          |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| DOT1L           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| G9A/GLP         |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| SUV420H1/H2     |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| SMYD2           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| SETD7           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRMT Type 1     |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRMT3           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRMT4           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRMT4/6         |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| PRMT5           |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| % IFN-γ\textsuperscript{+} of viable CD4\textsuperscript{+} cells |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
| IFN-γ (pg/mL)   |     |     |       |        |        |         |         |         |         |        |         |       |         |         |            |       |       |        |         |         |
Fig. 4 Differential Effects of PMT Inhibition on Murine and Human Th1 Cell Differentiation. a, b CD4+ T cells from the spleen and peripheral lymph nodes of IFN-γ-YFP reporter mice were enriched and polarized under Th0 (IL-2) or Th1 cell conditions in the absence (Th0) or presence of indicated probes (1 μM; red) or their controls (where available; black). a Flow cytometric analysis of intracellular YFP reporter signal (representing IFN-γ expression) was detected at day 4. b Secreted IFN-γ was analyzed by ELISA in the supernatant of the same experiment. Each data point represents one of three biological replicates and the data shown is representative of three independent experiments. c, d CD4+ T cells from the blood of three healthy human donors were cultured under Th0 or Th1 cell-polarizing conditions in the presence or absence of indicated probes or their controls. c Flow cytometric analysis of intracellular IFN-γ was detected at day 4. d Secreted IFN-γ was analyzed by ELISA in the supernatant of the same experiment. Each data point represents one of three donors. Dotted lines visualize the mean frequency of IFN-γ-positive Th1 cells in the absence of probes (a, c) or the mean concentration of IFN-γ in the supernatant (b, d). Significant differences are indicated with an asterisk and were calculated using one-way ANOVA (p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). e Western blot analysis of the effect of indicated inhibitors (red) or control compounds (black) on the trimethylation of H3K27 and dimethylation of H3K79 in CD4+ T cells under Th1, Th2, Th17, Treg cell-polarizing conditions. Please see Supplementary Figs. 5a-5d for information on the MW markers. Data shown is representative of 2 independent experiments. Error bars represent SEM. See also Supplementary Figs. 2-5.

 blot analysis of H3K79me2 in the presence of SGC0946 showed an almost complete global loss of H3K79me2, but showed no change with the inactive SGC0649 or with the inhibitors of the PRC2 complex (A-395 or UNC1999) (Fig. 4e and Supplementary Fig. 5). Importantly, this specific inhibition was consistent across Th1, Th2, Th17, and Treg cells. Thus, inhibition of specific histone methyltransferases and subsequent loss of their specific histone methylation marks was associated with phenotypic changes in mouse Th cells.

PMT regulation of Th1 cell responses is conserved in humans. To determine whether human T cells responded in a manner similar to mouse T cells, we activated human naïve peripheral blood CD4+ T cells for 4 days in the presence of Th1 cell-polarizing conditions. Consistent with our results for murine Th cells, inhibition of PRC2 (UNC1999, GSK343, A-395) and DOT1L (SGC0946) potentiated the effects of Th1 cell activation, resulting in a higher frequency of IFN-γ-producing Th1 cells as well as increased IFN-γ production, while the controls had no effect (Fig. 4c, d, and Supplementary Fig. 4). These results identify a central role for PRC2 and DOT1L in limiting Th1 cell differentiation in mice and humans.

Since to our knowledge DOT1L has not been examined in Th1 cell differentiation and function, we further investigated this enzyme using our mouse reporter system. In this four-day polarization assay, we only observed an enhancement of IFN-γ production with DOT1L inhibition if the cells were treated starting from day 0 or 1 of the culture, but not if the cells were exposed to the probe for only the last 1 or 2 days of polarization (Supplementary Fig. 3c). This is consistent with literature showing that reduction of histone methyl marks is dependent on the duration of exposure to methyltransferase inhibitors, often requiring days of exposure. To explore the dynamics of H3K79me2 during Th1 cell differentiation, we monitored the reduction of H3K79me2 and the production of IFN-γ over a period of 4 days (Fig. 5). Western blot analysis of global H3K79me2 shows that the mark is reduced in Th cells following activation in the presence of the control compound SGC0649 (Fig. 5a), suggesting that Th cell activation alone leads to a reduction of H3K79me2 independent of DOT1L inhibition. However, inhibition of DOT1L by addition of SGC0946 resulted in further reduction of H3K79me2 by day 2 that was maintained until day 4 post activation (Fig. 5a). This earlier and increased reduction of H3K79me2 induced by SGC0946 correlated with heightened IFN-γ levels (Fig. 5b). These data establish a correlation between reduction of the H3K79me2 mark and enhanced production of IFN-γ and validate that reduced H3K79me2 correlates with increased production of IFN-γ under Th1 cell-polarizing conditions. To assess whether DOT1L inhibition affected T cell proliferation, we used flow cytometric tracking of naïve Th cells labeled with a fluorescent dye (CFSE), and stimulated under either neutral (Th0) or Th1 cell-polarizing conditions in the presence of SGC0946 or SGC0649. We observed no effect on T cell proliferation (Supplementary Fig. 3d), suggesting that DOT1L inhibition likely affects the Th1 cell differentiation program without altering proliferative capacity.

We next carried out unbiased gene expression analysis. naïve Th cells from IFN-γ-YFP mice were stimulated under Th1 cell-polarizing conditions for 4 days in the presence of SGC0946 or SGC0649. IFN-γ+ CD4+ Th1 cells were purified by cell sorting, and RNA was isolated for RNA-Seq analysis. Comparing SGC0946- and SGC0649-treated IFN-γ-positive Th1 cells, we observed 750 genes that were significantly upregulated, with 208 genes downregulated when DOT1L was inhibited (Fig. 5c). We observed that inhibition of DOT1L led to expression of non-canonical genes for Th1 cells including perforin 1 (Prf1), a7 integrin subunit (Itga7), and Ly6G (Ly6g). Thus, our data suggest that DOT1L-dependent mechanisms are potentially important for limiting Th1 cell differentiation and maintaining lineage integrity.

PMTs differentially regulate Th cell differentiation. We next extended our analysis of the probe collection to identify PMTs that may be involved in differentiation of not only Th1, but also Th2, Th17 or Treg cells. We activated naïve Th cells from either wild-type C57BL/6 mice or transgenic reporter mice (IFN-γ-YFP, IL-4-GFP, or FOXP3-EGFP) under Th1, Th2, Th17 or Treg cell differentiation conditions for four days in the absence or presence of PMT probes or control compounds, and analyzed expression of lineage-specific markers such as cytokines (Fig. 6) or transcription factors (Supplementary Fig. 7). As summarized in Fig. 6, we found a wide range of effects on T cell differentiation both between different probes as well as between different stimulation conditions for a single probe or chemotype. For example, inhibition of DOT1L and the PRC2 complex (EZH1/2, EED) enhanced effector cell differentiation (Th1, Th2, and Th17) with no effect on Treg cell development, while inhibition of G9a/GLP (UNC0642, A-366), strongly affected Treg cell differentiation. These data are consistent with our previous results demonstrating a key role for G9a in promoting Treg cell function.

Another chemical probe that showed strong promotion of Treg cell differentiation is MS023 which inhibits the type I PRMT enzymes, PRMT1, 3, 4, 6, and 8. PRMT8 is a neuronal-specific enzyme and not expressed in T cells. MS023 was not tested on PRMT2 because the latter has not yet been demonstrated to be an active methyltransferase enzyme. Comparison of this result with that of the more selective probes for PRMT3 (SGC707), PRMT4 (TP-064) and PRMT4/6 (MS049) all of which had little or no effect on Treg differentiation, suggests that the primary effect of MS023 is due to inhibition of PRMT1. This screen suggests potential strategies for promotion of Treg cell differentiation through inhibition of type I PRMTs, or PRMT1, should
a selective PRMT1 probe become available. Such compounds may be beneficial to subdue aberrant inflammatory immune responses.

Inhibition of PRMT5 using peptide competitive (GSK591) and SAM competitive (LLY-283) chemical probes clearly down-regulated the signature cytokines for effector cell differentiation, but also significantly increased cell death (Supplementary Fig. 7). PRMT5 has been shown to be required for growth and viability of rapidly proliferating cells such as cancer cell lines. Although the mechanisms are not fully understood, PRMT5 knockdown slows the cell cycle in NIH3T3 cells and induces G1 arrest in 293T and MCF7 cells. It is possible that similar mechanisms are at play in proliferating Th cells. The effect of PRMT5 on Treg cell differentiation is unclear since the chemical probes yielded opposite results (even across 6 biological replicates).

**Discussion**

Here we present a collection of chemical biology reagents to modulate cellular methylation signaling, especially chromatin-mediated signaling. Each probe has been characterized for its selectivity within the human SET and PRMT methyltransferase families. Most of our chemical probes are accompanied by structurally similar inactive compounds that serve as negative controls for potential off-target effects of their common chemical scaffold. We have annotated the chemical structure of each chemical probe showing where they can be chemically derivatized to create additional reagents such as biotinylated probes for chemoproteomics. Using several examples of such derivatives we demonstrate the cellular selectivity for their targets and respective interacting proteins. Importantly, these probes and related compounds may be used for research without restrictions.

Using our collection of PMT chemical probes, we identified several PMTs that differentially regulate Th cell differentiation. For example, inhibition of the PRC2 complex led to enhanced Th1, Th2 and Th17 cell responses and a reduction in Treg cell development, which is consistent with the phenotype observed in mice with a genetic deletion of EZH2. In addition, inhibition of G9a resulted in a significant increase in the frequency of FOXP3-expressing Treg cells, which is in agreement with our previous results. Our unbiased screen also identified regulators of Th cell differentiation. Inhibition of DOT1L promoted effector Th cell responses with little effect on Treg cell differentiation, as did type I PRMT inhibition. While the potential enhancement of a regulatory immune response by inhibitors of G9a or by members of the Type I PRMT family may be beneficial to control immune responses in inflammatory disease, an increase of pro-inflammatory responses by inhibiting the PRC2 complex or DOT1L might be beneficial to boost the immune response in underperforming immune systems. These results warrant further investigation given the intense interest in T cell biology and the growing appreciation for the role of epigenetics in T cell differentiation. Thus, the PMT chemical probe library provides a toolbox to examine the biological role of methylation-mediated signaling in cellular assays.
One striking finding from our results is that specific probes displayed diverse functional effects on distinct Th cell subsets despite global reductions in their respective specific histone modification in all subsets examined. For example, inhibition of DOT1L led to heightened effector T cell responses with minimal effects on Treg cells, while inhibition of G9a primarily affected Th17 and Treg cells. Although the precise molecular mechanisms are yet to be elucidated, these results suggest that the targeted epigenetic modifiers do not act in isolation but rather collaborate with lineage-specific factors that are expressed in the specific Th cell subsets. As the PMTs do not have sequence-specific DNA-binding domains, Th cell subset-specific accessory factors that target PMTs to the chromatin will be critical modulators of function. In addition, it is possible that non-histone substrates of PMTs are critically important in some Th cell subsets. Thus, this chemical probe library provides tools to examine the fundamental mechanisms associated with epigenetic regulation of Th cells.

Among the targets in our chemical probe collection, several have agents currently in clinical trials for cancer (EZH2, EED, DOT1L, PRMT1, and PRMT5) and additional PMT inhibitors are in preclinical studies. The availability of well characterized, unencumbered chemical probes for such targets will enable the research community to better understand the mechanisms and consequences of PMT inhibition in a wide variety of cellular contexts providing important knowledge to help guide clinical development, patient stratification, and novel applications of PMT inhibitors. Of particular interest are the apparent pro-inflammatory activities of PRC2 and DOT1L inhibitors, which warrant further investigation in the immune-oncology setting.

Overall, our collection of 19 chemical probes to 16 PMT targets, 17 chemotype-matched controls, and 18 related chemical biology reagents will be an outstanding resource to enable research in methylation-dependent epigenetic regulation. Our detailed descriptions of the potency, selectivity and structural mechanisms of inhibition of each chemical probe provide a comprehensive overview of this target class and should facilitate the development of new chemical probes to other PMTs. Additional uses of the collection may include (i) synthetic lethal screens of the probes versus genetic ablation of individual genes in cancer, (ii) screens for optimal combinations of PMT probes with existing standard of care therapies in cellular disease models, (iii) investigation of endogenous PMT protein complexes in a variety of cells without the need to introduce tagged exogenous protein baits, and (iv) development of protein degrading reagents through derivatization of chemical probes.

### Methods

#### Methyltransferase selectivity assays.

The effects of chemical probes and negative controls on the methyltransferase activities of protein, DNA and RNA methyltransferases were tested by radiometric assays using 3H-SAM. For proteins such as MLL1 trimeric complex, MLL3 pentameric complex, EZH1 (PRC2) trimeric complex, EZH2 (PRC2) trimeric complex, as well as G9a, GLP, SUV39H1, SUV39H2, SUV420H1, SUV420H2, SETD2, SETD8, SETD7, SETD7, PRMT1, PRMT3, PRMT4, PRMT5, MEPS0 complex, PRMT6, PRMT7, PRMT8, PRMT9, PRDM9, SMYD2, SMYD3, DNMT1 and BCDIN3D the incorporation of a tritium-labeled methyl group into biotinylated substrate (Supplementary Table 3) was monitored using scintillation proximity assay (SPA). Briefly, a 10-μL reaction containing 3H-SAM and substrate at concentrations close to the apparent Km values for each enzyme (balanced conditions) was prepared. The reactions were quenched with 10 μL of 7.5 M guanidine hydrochloride; 180 μL of 20 mM Tris buffer (pH 8.0) were added, and the mixture was transferred to a 96-well FlashPlate and incubated for 1 h. The counts per minute (CPM) was measured on a TopCount plate reader. The CPM in the absence of compound or enzyme was defined as 100% activity and background (0%), respectively, for each dataset.

For DNMT1, the double-stranded DNA substrate was prepared by annealing two complementary strands (biotinylated forward strand: 5′-GAGCCCGTAAGCGCGTTCAGGTCG and reverse strand: CGACCTGAACGGGCTTACGGGCTC) that were synthesized by Eurofins MWG Operon (Louisville, KY, USA). For proteins which were tested with nucleoside as substrate such as DOT1L, NSD1, NSD2, NSD3 and ASH1L, or unbiotinylated Poly(2′-deoxycytosinic-2′-deoxycytidylic acid) (Cat# 81349-500UG, Sigma Aldrich) such as DNMT3A:3L and DNMT3B:3L, a filter-based assay was used. In this assay, a trichloroacetic acid (TCA) protein precipitation protocol was employed. A 10 μL reaction mixture was incubated at 23 °C for 1 h, followed by addition of 50 μL of 10% TCA and once with ethanol (180 μL), and centrifuged (as before). After drying, 100 μL MicroScint-O (Perkin Elmer) was added to each well and the plates were centrifuged to remove the liquid. A 70-μL volume of MicroScint-O was added and the CPM was measured with a TopCount plate reader.

---

**Fig. 6 Overview of PMT Inhibition on Murine CD4+ T cell Differentiation.** Data is presented as fold-increase (black) or decrease (red) of cytokine production (IFN-γ, IL-17, and IL-17A for Th1, Th2, and Th17 cells, respectively) or FOXP3 expression (Treg cells) over that of the control compound-treated (or untreated) cells. Data shown are from two to three individual experiments with three biological replicates each. *Significant cell death observed compared to DMSO control. See also Supplementary Figs. 6 and 7.
Mice. C57BL/6 mice and reporter mice for IFN-γ, IL-4, or Foxp3 were on C57BL/6 background for use in the polarization assays, where possible. Where unavailable, the non-immortalized naive CD4+ T cells were cultured under identical conditions (Mycoplasma-free). All cell lines tested negative for mycoplasma contamination (MycoAlertTM kit, Lonza). Cell lines were grown in DMEM Medium containing 10% FBS, respectively. The cell lines are not found in 12 NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07905-4 | www.nature.com/naturecommunications

ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07905-4

compounds were not replenished over the duration of the experiment. Naïve CD4+ twenty thousand naïve CD4+ T cells were cultured under identical conditions44. Here, 175,000 naïve CD4+ T cells were cultured under identical conditions for 4 days in the presence of chemical probes or their respective controls. Viability of the cells was determined using a viability cocktail (ThermoFisher Cat# 65-0863-18; 1:1000). Signature cytokines and transcription factors were detected using reporter mice or by intracellular staining 4 h after the cytokine stimulation cocktail (ThermoFisher Cat# 0-4975-03; 1:500) and antibodies against TBE (eBioB10; ThermoFisher Cat# 25-5825-82; 1/ 200), GATA3 (TWA1; ThermoFisher Cat# 12-9966-42; 1:200), RORγt (B2D; ThermoFisher Cat# 25-7733-82; 1/100), FoxP3 (FJK-11D2; 1/100; 200), and IL-2 (IL-2-1, IL-2-10 ng mL−1 each), anti-IL-4 (10 ng mL−1), IL-10 (10 ng mL−1 each), anti-IFN-γ (10 ng mL−1) and recombinant IL-2 (10 ng mL−1) for 4 days in the presence of recombinant IL-12 (10 ng mL−1), anti-IL-4 antibody (10 ng mL−1) and recombinant IL-2 (10 ng mL−1) for 4 days and as used as a control. Cells were stained with SYTOXO34 Blue Dead Cell Stain (Thermo Fisher Scientific), fixed, and permeabilized, followed by the intracellular staining with anti-IFN-γ antibody. All healthy volunteers accepted to donate their blood samples for research purposes by signing an informed consent (Mount Sinai Hospital, Research Ethics Board #02-0234-E).

RNA-Seq and bioinformatics. Naïve CD4+ T cells (CD44neg (Thermo Fisher Scientific Cat# 04-4441-80; 1/200), CD46Lhi (Thermo Fisher Scientific Cat# 25-8621-82; 1/200) and CD4+ T cells positive (IFN-γ) or negative (IFN-γ) for YFP after Th1 polarization were sorted and total RNA was extracted using the Nucleospin RNA kit (Machery-Nagel), according to the manufacturer’s instructions. RNA was isolated with an mRNA kit (TruSeq Stranded; Illumina, San Diego, CA, USA) and sequenced on a MiSeq paired-end run (75 × 75, v3; Illumina). Samples were aligned to the mm10 transcript reference using TopHat2, and differential expression was assessed using Cufflinks (Illimina). Visualization of the data was performed using DEGUST [https://github.com/dropwell/degust] and represent the average expression from 3 biological replicates (x-axis) and the Log2 fold change of SGO6946-treated cells over SGO6949-treated cells (y-axis).

Western blot assays. Enriched CD4+ T cells were cultured in the absence (Th1) or presence of indicated clinical probes for 4 days (or as indicated in the experiment) under Th1 polarizing conditions. Cells were harvested and pellets were frozen at −80 °C. Histones were extracted from frozen cell pellets by incubating in 0.2 N HCl overnight at 4 °C. Supernatants were run on 12% SDS-PAGE gels. H3K27me3 and H3K97me2 were detected using clones ab6002 and ab3594 (Abcam), respectively. A pan anti-histone H3 antibody (ab7197, Abcam) at a concentration of 1 μg mL−1 was used as a loading control. The uncropped blots are shown in Supplementary Fig. 5.

Chemical proteomics. G401, Jurkat and HEK293T were obtained from ATCC (Virginia, USA) and cultured at 37 °C in a humidified 5% CO2 atmosphere in McCoy’s 5-Medium containing 10% FBS, RPMI-1640 containing 10% FBS, and DMEM Medium containing 10% FBS, respectively. The cell lines are not found in the ICLAC database for commonly misidentified cell lines, and were not authenticated by any cell line laboratories. Loaded beads were incubated with each of the peptides (Figure 1A) for 30 min at room temperature, diluted to 300 μL with TEAB, and incubated with trypsin (6 μg mL−1) overnight at 37 °C. The digests were then desalted using SEPAc lite columns (Waters), eluted with 69% v/v MeCN, 0.1% v/v FA in H2O (1 mL) and dried in vacuo. Dried peptides were stored at −20 °C before resuspension in 2% v/v MeCN, 0.1% v/v FA in H2O (20 μL) for LC-MS/MS analysis.

Mass spectrometry data were acquired at the Discovery Proteomics Facility (University of Oxford). Digested samples were analyzed by nano-UPLC-MS/MS using a Dionex Ultimate 3000 nano UPLC with EASY spray column (75 μm × 500 mm, 2 μm particle size, Thermo Scientific) with a flow rate of 0.5–1 μL min−1, for 30 min at room temperature, diluted to 300 μL with TEAB, and incubated with trypsin (6 μg mL−1) overnight at 37 °C. The digests were then desalted using SEPAc lite columns (Waters), eluted with 69% v/v MeCN, 0.1% v/v FA in H2O (1 mL) and dried in vacuo. Dried peptides were stored at −20 °C before resuspension in 2% v/v MeCN, 0.1% v/v FA in H2O (20 μL) for LC-MS/MS analysis.

Raw data was processed using MaxQuant version 1.5.253 and the reference decoy database (Proteome Xchange). For protein quantification, the ion count of each selected MS1 peak was used for the quantitation (LFQ) and Match Between Runs were selected; replicates were collated into parameter matrices to ensure matching between replicates only. Cysteine carboxamidomethylation was selected as a fixed modification, and methionine oxidation as a variable modification. Default settings for identification and quantification were used. Specifically, a minimum peptide length of 7, a maximum of 2 missed cleavage sites, and an FDR of 0.01% was set. Data was exported as top hits of the ‘trypsin/P’ general setting, peptide bond cleavage at arginine or lysine (followed by any amino acid) was considered during in silico digest of the reference proteome. The allowed precursor and fragment ion mass tolerances were 0.8 and 2.5 ppm, respectively. For protein quantification, the ion count of each selected MS1 peak was used for the quantitation (LFQ) and Match Between Runs were selected; replicates were collated into parameter matrices to ensure matching between replicates only. Cysteine carboxamidomethylation was selected as a fixed modification, and methionine oxidation as a variable modification. Default settings for identification and quantification were used. Specifically, a minimum peptide length of 7, a maximum of 2 missed cleavage sites, and an FDR of 0.01% was set. Data was exported as top hits of the ‘trypsin/P’ general setting, peptide bond cleavage at arginine or lysine (followed by any amino acid) was considered during in silico digest of the reference proteome. The allowed precursor and fragment ion mass tolerances were 0.8 and 2.5 ppm, respectively.
4.5 ppm and 20 ppm, respectively. Peptides and proteins were identified utilizing a 0.01 false discovery rate, with “Unique and razor peptides” mode selected for both identification and quantification of proteins (razor peptides are uniquely assigned to protein groups and not to individual proteins). At least 2 razor + unique peptides were required for valid quantification. Processed data was further analyzed using Perseus version 1.5.0.9 and Microsoft Excel 2010. MaxQuant as ‘potential contaminants’, only identified by site’ or ‘reverse’ were filtered, and the LFQ intensities transformed by log2. Experimental replicates were grouped, and two valid LFQ values were required in at least one experimental group. Missing values were imputed using default settings, and the data distribution visually inspected to ensure that a normal distribution was maintained. Statistically significant competition was determined through the application of P2 tests, using a permutation-based FDR of 0.05 and an S0 of 2, and visualized in volcano plots. Significantly competed targets were further analyzed in STRING (http://string-db.org) and protein interaction networks generated. Basic STRING settings were used for network analysis of enriched proteins. Specifically, network edges represent confidence in interaction. Line thickness indicates the strength of data support with a minimum required interaction score of 0.400. All active interaction sources (Textmining, Experiments, Databases, Co-expression, Neighborhood, Gene Fusion, Co-occurrence) were considered.

Syntheses of reagents. The syntheses of the reagents are described in the Supplementary Information.

Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The proteomics data that support the findings of this study have been deposited in the PRIDE partner repository62(ProteomeXchange Consortium) with the dataset identifier PXD009028. The RNA-Seq data that support the findings of this study are available at the National Center for Biotechnology Information with the primary accession code GSE109798. All other data that support the findings of this study are available from the corresponding author on reasonable request. A reporting summary for this Article is available as a Supplementary Information file.

Received: 20 February 2018 Accepted: 4 December 2018 Published online: 03 January 2019

References

1. Mendenhall, E. M. et al. Locus-specific editing of histone modifications at endogenous enhancers. Nat. Biotechnol. 31, 1133–1136 (2013).
2. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384–400 (2012).
3. Shortt, J.-C., Ott, C. J., Johnstone, R. W. & Bradner, J. E. A chemical probe toolbox for dissecting the cancer epigenome. Nat. Rev. Cancer 17, 160–183 (2017).
4. Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541 (2015).
5. Wäsche, J., Kuhn, S., Kessler, B. M., Salton, M. & Wolf, A. Protein arginine methyltransferase: a promising modification and its demethylation. Cell Mol. Life Sci. 74, 3305–3315 (2017).
6. Wu, Z., Connolly, J. & Biggar, K. K. Beyond histones - the expanding roles of protein lysine methylation. FEBS J. 284, 2732–2744 (2017).
7. Ribich, S., Harvey, D. & Copeland, R. A. Drug discovery and chemical biology of cancer epigenetics. Cell Chem. Biol. 24, 1120–1147 (2017).
8. Hamamoto, R., Saloura, V. & Nakamura, Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat. Rev. Cancer 15, 110–124 (2015).
9. Bush, Z. Y., Lyu, Z. & Wang, R. E. Interrogating the roles of post-translational modifications of non-histone proteins. J. Med. Chem. 61, 3239–3252 (2018).
10. Liu, F. et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J. Med. Chem. 56, 8931–8943 (2012).
11. Konze, K. D. et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324–1334 (2013).
12. Yu, W. et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288 (2012).
13. Bromberg, K. D. et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat. Chem. Biol. 13, 317–324 (2017).
14. Grebien, F. et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-terminal leukemia. Nat. Chem. Biol. 11, 571–578 (2015).
15. Huang, J. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629–632 (2006).
47. Reinhardt, R. L., Liang, H. E. & Locksley, R. M. Cytokine-secreting follicular T cells shape the antibody repertoire. *Nat. Immunol.* **10**, 385–393 (2009).
48. Zhang, Y. et al. The polycomb repressive complex 2 governs life and death of peripheral T cells. *Blood* **124**, 737–749 (2014).
49. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. *Cancer Cell* **20**, 53–65 (2011).
50. Vedadi, M. et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. *Proc. Natl. Acad. Sci. USA* **108**, 17370–17375 (2011).
51. Penney, J. et al. Loss of protein arginine methyltransferase 6 alters synapse composition and function, resulting in behavioral defects. *J. Neurosci.* **37**, 8655–8666 (2017).
52. Lakowski, T. M. & Frankel, A. Kinetic analysis of human protein arginine N-methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-arginine residues on histone H4. *Biochem. J.* **421**, 253–261 (2009).
53. Gulla, A., et al. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. *Leukemia* **32**, 996–1002 (2017).
54. Wei, T. Y. et al. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. *Cancer Sci.* **103**, 1640–1650 (2012).
55. Scoumanne, A., Zhang, J. & Chen, X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. *Nucleic Acids Res.* **37**, 4965–4976 (2009).
56. Pace, L. et al. The epigenetic control of stemness in CD8(+) T cell fate commitment. *Science* **359**, 177–186 (2018).
57. Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8 (+) T cell differentiation. *Nat. Rev. Immunol.* **18**, 340–356 (2018).
58. Naito, T., Muroi, S., Taniuchi, I. & Kondo, M. Loss of Eed leads to lineage commitment. *Cell* **174**, 18480–18493 (2018).
59. Shen, Y. et al. Discovery of a potent, selective, and cell-active dual inhibitor of PRMT4 for multiple myeloma. *J. Med. Chem.* **59**, 9124–9139 (2016).

Acknowledgements

We thank our numerous medicinal chemistry collaborators in the pharmaceutical industry, the Ontario Institute for Cancer Research (OICR), and the Jin, Frye, and Luo laboratories. The remaining authors declare no competing interests.

Author contributions

S.S. performed murine T cell experiments. T.S.M. performed human T cell experiments. J.A.W. and A.M.L. performed proteomics experiments. J.P.N. performed western blots. F.L. performed vitro PMT assays. M.S. analyzed protein structures. D.S., D.M., H.U.K., Y.S., P.L.R., C.A.Z.-V. and J.L. synthesized compounds. M.L., C.Z., D.D.C., K.V.M.H., F.L. performed vitro PMT assays. M.S. analyzed protein structures. D.S., D.M., H.U.K., Y.S., P.L.R., C.A.Z.-V. and J.L. synthesized compounds. M.L., C.Z., D.D.C., K.V.M.H., F.L. performed vitro PMT assays. M.S. analyzed protein structures. D.S., D.M., H.U.K., Y.S., P.L.R., C.A.Z.-V. and J.L. synthesized compounds. M.L., C.Z., D.D.C., K.V.M.H., F.L. performed vitro PMT assays. M.S. analyzed protein structures. D.S., D.M., H.U.K., Y.S., P.L.R., C.A.Z.-V. and J.L. synthesized compounds.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019